Company Registration No. 08379504 (England and Wales)
HEALTH ELIXIR LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 JANUARY 2025
PAGES FOR FILING WITH REGISTRAR
Bickland House
Bickland Water Road
Falmouth
Cornwall
TR11 4SB
HEALTH ELIXIR LIMITED
CONTENTS
Page
Company information
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
HEALTH ELIXIR LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2025
31 January 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
49,999
65,384
Tangible assets
4
9,588
12,182
59,587
77,566
Current assets
Stocks
27,108
25,184
Debtors
5
45,476
52,882
Cash at bank and in hand
222,933
154,489
295,517
232,555
Creditors: amounts falling due within one year
6
(98,783)
(72,882)
Net current assets
196,734
159,673
Total assets less current liabilities
256,321
237,239
Provisions for liabilities
(2,397)
(3,046)
Net assets
253,924
234,193
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
253,922
234,191
Total equity
253,924
234,193
HEALTH ELIXIR LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JANUARY 2025
31 January 2025
- 2 -

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 8 October 2025
Mr F Baig
Director
Company registration number 08379504 (England and Wales)
HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025
- 3 -
1
Accounting policies
Company information

Health Elixir Limited is a private company limited by shares incorporated in England and Wales. The registered office is 12 Kings Road, St Mawes, TRURO, Cornwall, England, TR 2 5DH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recover ed.

HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
1
Accounting policies
(Continued)
- 4 -
1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is [XXXX].

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% on cost
Fixtures and fittings
15% on cost
Computers
20% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
4
3
HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
- 6 -
3
Intangible fixed assets
Total
£
Cost
At 1 February 2024 and 31 January 2025
200,000
Amortisation and impairment
At 1 February 2024
134,616
Amortisation charged for the year
15,385
At 31 January 2025
150,001
Carrying amount
At 31 January 2025
49,999
At 31 January 2024
65,384
4
Tangible fixed assets
Total
£
Cost
At 1 February 2024
34,722
Additions
1,057
Disposals
(298)
At 31 January 2025
35,481
Depreciation and impairment
At 1 February 2024
22,540
Depreciation charged in the year
3,651
Eliminated in respect of disposals
(298)
At 31 January 2025
25,893
Carrying amount
At 31 January 2025
9,588
At 31 January 2024
12,182
HEALTH ELIXIR LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
- 7 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
1,515
10,572
Other debtors
6,498
3,190
Prepayments and accrued income
37,463
39,120
45,476
52,882
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
20,230
23,956
Corporation tax
19,374
21,634
Other taxation and social security
816
587
Other creditors
55,402
24,406
Accruals and deferred income
2,961
2,299
98,783
72,882
7
Ultimate controlling party

The ultimate controlling party is Mr F Baig.

2025-01-31 2024-02-01 false false false 08 October 2025 CCH Software CCH Accounts Production 2025.200 No description of principal activity Mr Faisel Baig 08379504 2024-02-01 2025-01-31 08379504 2025-01-31 08379504 2024-01-31 08379504 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 08379504 core:CurrentFinancialInstruments core:WithinOneYear 2024-01-31 08379504 core:CurrentFinancialInstruments 2025-01-31 08379504 core:CurrentFinancialInstruments 2024-01-31 08379504 core:ShareCapital 2025-01-31 08379504 core:ShareCapital 2024-01-31 08379504 core:RetainedEarningsAccumulatedLosses 2025-01-31 08379504 core:RetainedEarningsAccumulatedLosses 2024-01-31 08379504 bus:Director1 2024-02-01 2025-01-31 08379504 core:Goodwill 2024-02-01 2025-01-31 08379504 core:PlantMachinery 2024-02-01 2025-01-31 08379504 core:FurnitureFittings 2024-02-01 2025-01-31 08379504 core:ComputerEquipment 2024-02-01 2025-01-31 08379504 2023-02-01 2024-01-31 08379504 2024-01-31 08379504 bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 08379504 bus:SmallCompaniesRegimeForAccounts 2024-02-01 2025-01-31 08379504 bus:FRS102 2024-02-01 2025-01-31 08379504 bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 08379504 bus:FullAccounts 2024-02-01 2025-01-31 xbrli:pure xbrli:shares iso4217:GBP